Home Journals Articles Updates About
CN
image
收藏切换
Research progress of ATR kinase-targeted inhibitors in the cancer therapy
收藏切换
PDF
Ying-hui YUAN, Ji-long DUAN, Zi HUI*, Tian XIE*, Xiang-yang YE*
Acta Pharmaceutica Sinica | 2022, 57(3) : 593 - 604
Less
收藏切换
Acta Pharmaceutica Sinica | 2022, 57(3): 593-604
• Reviews •
Research progress of ATR kinase-targeted inhibitors in the cancer therapy
Full
Ying-hui YUAN, Ji-long DUAN, Zi HUI*, Tian XIE*, Xiang-yang YE*
Affiliations
  • School of Pharmacy; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou 311121, China
Published: 2022-03-12 doi: 10.16438/j.0513-4870.2021-1522
Outline
收藏切换

Cancer, also known as malignant tumor, is the second largest disease after heart disease, which is characterized by genomic instability and mutagenicity. Ataxia telangiectasia and RAD3-related kinase (ATR) are members of phosphatidylinositol 3-kinase (PIKK) family, belonging to serine/threonine kinase, one of the key kinases in DNA damage response (DDR) and DNA repair pathway. This paper reviews the latest progress in the ATR inhibitor field including mechanism of action (MOA), therapeutic applications, and the combination therapy from the perspective of medicinal chemistry. It also discusses the possible challenges and future directions of developing ATR inhibitor antitumor drugs, which could provide the scientists in this field the convenience for access the information and application guidance for clinical studies.

cancer  /  ATR kinase  /  inhibitor  /  clinical research  /  combinational medication
Ying-hui YUAN, Ji-long DUAN, Zi HUI, Tian XIE, Xiang-yang YE. Research progress of ATR kinase-targeted inhibitors in the cancer therapy[J]. Acta Pharmaceutica Sinica, 2022 , 57 (3) : 593 -604 . DOI: 10.16438/j.0513-4870.2021-1522
Appendix
Less
Year 2022 volume 57 Issue 3
PDF
221
99
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2021-1522
  • Receive Date：2021-10-21
  • Online Date：2025-12-22
  • Published：2022-03-12
Article Data
Affiliations
History
  • Received：2021-10-21
  • Revised：2021-11-09
Funding
Affiliations
    School of Pharmacy; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou 311121, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2021-1522
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House